Clinical trials: B-Cell Lymphoblastic Leukemia/Lymphoma
Lymphomas Non-Hodgkin's B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment
The purpose of this first-in-human study is to evaluate the safety and tolerability of INT2104 when administered to humans in a broad population of participants with refractory/relapsing B-cell malignancies.
- Trial name
- INVISE (NCT06539338)
- Testing
- INT2104
- Where
- 3 sites in Australia, Spain
- Volunteers
- 10 people
- Sponsor
- Kite, A Gilead Company
Lymphoma
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma
RATIONALE: Diagnostic imaging procedures, such as radiolabeled monoclonal antibodies, may improve the ability to detect the residual disease in patients who have been treated for non-Hodgkin's lymphoma.
- Trial name
- NCT00003338
- Testing
- immunoscintigraphy, technetium Tc 99m epratuzumab
- Where
- 8 sites in United States, Austria and 3 more
- Volunteers
- 60 people
- Sponsor
- Gilead Sciences
Acute Lymphoblastic Leukemia, B Cell Lymphoma
Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies
This is the second stage of the previous anti-CD19 CAR-T therapy (NCT02965092). The study aims to evaluate the safety and efficacy of consolidative allo-HSCT following CAR-T therapy in patients with relapsed or refractory B cell…
- Trial name
- NCT03366350
- Testing
- Allogeneic hematological stem cell transplantation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Wuhan Sian Medical Technology Co., Ltd
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer.
- Conditions
- Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
- Trial name
- BRUIN-CLL-314 (NCT05254743)
- Testing
- Pirtobrutinib, Ibrutinib
- Where
- 143 sites in United States, Argentina and 21 more
- Volunteers
- 737 people
- Sponsor
- Loxo Oncology, Inc.
B-cell Follicular Lymphoma, B-cell Marginal Zone Lymphoma
Study of MLN8237 in Participants With Advanced Hematological Malignancies
This is an open-label, multicenter, phase 1 study of MLN8237 in participants with advanced hematological malignancies for whom there are limited standard treatment options.
- Conditions
- B-cell Follicular Lymphoma, B-cell Marginal Zone Lymphoma, Diffuse Large B-cell Lymphoma, B-cell Mantle Cell Lymphoma
- Trial name
- NCT00697346
- Testing
- Alisertib
- Where
- 10 sites in United States
- Volunteers
- 58 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Lymphoid Malignancies
A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies
This study is to determine the appropriate dosing regimen of GS-9820 in subjects with lymphoid malignancies. This is a Phase 1b, open-label, dose-escalation and expansion study evaluating the safety, pharmacokinetics…
- Trial name
- NCT01705847
- Testing
- GS-9820
- Where
- 4 sites in Netherlands
- Volunteers
- 39 people
- Sponsor
- Gilead Sciences
Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL)
Study of XL114 in Subjects With Non-Hodgkin's Lymphoma
This is a Phase 1, non-randomized, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical antitumor activity of XL114…
- Conditions
- Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT05144347
- Testing
- XL114
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Exelixis
Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma
Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with TGR-1202, with or without ibrutinib or bendamustine, in patients with advanced hematologic malignancies
- Trial name
- NCT02006485
- Testing
- Ublituximab + TGR-1202, Ublituximab + TGR-1202 + ibrutinib, Ublituximab + TGR-1202 + bendamustine
- Where
- 6 sites in United States
- Volunteers
- 160 people
- Sponsor
- TG Therapeutics, Inc.
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to establish the safety of orally administered PCI-32765 in combination with fludarabine/cyclophosphamide/rituximab (FCR) and bendamustine/rituximab (BR) in patients with chronic lymphocytic leukemia…
- Trial name
- NCT01292135
- Testing
- PCI-32765
- Where
- 6 sites in United States
- Volunteers
- 33 people
- Sponsor
- Pharmacyclics LLC.
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies
The primary objective of the study is to evaluate efficacy of entospletinib in participants with relapsed or refractory hematologic malignancies.
- Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Non-FL Indolent Non-Hodgkin's Lymphoma
- Trial name
- NCT01799889
- Testing
- Entospletinib MM, Entospletinib SDD
- Where
- 48 sites in United States, Canada
- Volunteers
- 326 people
- Sponsor
- Gilead Sciences
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL who have not been treated. Participation could last up to five years.
- Trial name
- BRUIN-CLL-313 (NCT05023980)
- Testing
- Pirtobrutinib, Bendamustine, Rituximab
- Where
- 108 sites in United States, Australia and 18 more
- Volunteers
- 282 people
- Sponsor
- Loxo Oncology, Inc.
Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma
The purpose of this study is to evaluate the safety and optimal dose of PCAR-119 in patients who are going to receive stem cell transplantation but without available treatment to achieve complete remission prior to the transplant.
- Conditions
- Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT02892695
- Testing
- anti-CD19 CAR-NK cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia, B-cell Precursor Acute Lymphoblastic Leukaemia
Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.
The purpose of this study is to evaluate the pharmacokinetics, pharmacodynamics and safety of different doses of intravenous and oral Forodesine in children with relapsed or refractory T-cell or B-cell precursor Acute…
- Conditions
- Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia, B-cell Precursor Acute Lymphoblastic Leukaemia, T-cell Non-Hodgkin's Lymphoma
- Trial name
- BCX1777-108 (NCT00742495)
- Testing
- Forodesine
- Where
- 6 sites in Austria, Czechia and 4 more
- Volunteers
- 2 people
- Sponsor
- Mundipharma Research Limited
Leukemia, Chronic Lymphocytic Leukemia
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
This is a multicenter, 2-cohort Phase 2 study assessing both minimal residual disease (MRD)-guided discontinuation and fixed duration therapy with the combination of ibrutinib + venetoclax in subjects with treatment-naïve CLL or…
- Conditions
- Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- Captivate (NCT02910583)
- Testing
- ibrutinib, venetoclax
- Where
- 46 sites in United States, Australia and 4 more
- Volunteers
- 323 people
- Sponsor
- Pharmacyclics LLC.
Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
This will be a multicenter, national, non-interventional, prospective cohort study
- Conditions
- Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Follicular Lymphoma
- Trial name
- NCT05541341
- Testing
- tisagenlecleucel
- Where
- 7 sites in Brazil
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Hematologic Neoplasms
A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies
The primary objective of this study is to characterize the safety, tolerability, dose-limiting toxicities (DLTs), and maximum tolerated dose (MTD) of relatlimab administered alone or in combination with nivolumab to subjects with…
- Trial name
- NCT02061761
- Testing
- BMS-986016, BMS-936558
- Where
- 10 sites in United States, Canada
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb
B-precursor Acute Lymphoblastic Leukemia
Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
The study aims to determine the safety and feasibility of complete outpatient blinatumomab administration for subjects with minimal/measurable residual disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL).
- Trial name
- NCT04506086
- Testing
- Blinatumomab, Current Wearable Heatlth Monitoring System (CWHMS)
- Where
- 12 sites in United States
- Volunteers
- 10 people
- Sponsor
- Amgen
B-cell Non Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
Treatment of Hematological Malignancy With Novel CAR-T Cells.
This is a single arm, open-label, early phase I study, to determine the safety and efficacy of Novel CAR-T cell therapy in Hematological Malignancy treatment.
- Conditions
- B-cell Non Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia, Multiple Myeloma
- Trial name
- NCT04191941
- Testing
- Novel CAR-T
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Timmune Biotech Inc.
Leukemia, Lymphoma
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Leukemia, Lymphoma, Graft Versus Host Disease
- Trial name
- NCT00003056
- Testing
- cyclosporine, cyclosporine and methotrexate
- Where
- 13 sites in United States, Australia
- Volunteers
- 105 people
- Sponsor
- Baxalta now part of Shire
Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF)
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL
Objectives of this clinical trial are to evaluate the safety, tolerability, pharmacokinetics and potential efficacy of the investigational drug, cobomarsen (MRG-106), in patients diagnosed with certain lymphomas and leukemias…
- Conditions
- Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma (DLBCL), ABC Subtype
- Trial name
- NCT02580552
- Testing
- Cobomarsen
- Where
- 19 sites in United States
- Volunteers
- 66 people
- Sponsor
- miRagen Therapeutics, Inc.